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Multiple myeloma (MM) is a plasma cell neoplasm localized in the bone marrow (BM). Autologous stem cell transplantation and novel agents, like proteasome inihibitors (Velcade) and immunomodulatory agents (thalidomide and lenalidomide), have significantly improved the treatment of MM patients. 1 However, this type of cancer still remains incurable. T-lymphocyte-mediated immunotherapy has been considered as a potential new avenue for the treatment of MM, based on the observations that MM cells can be recognized and lysed by CD4 þ and CD8 þ cytotoxic T cells. 2 However, dysfunction of immune cells (T cells, dendritic cells, B cells) and an immunosuppressive BM microenvironment are described in MM patients, although the mechanisms governing this immunosuppression are not well characterized. 3, 4 Revealing the mechanisms of immunodeficiency in MM patients could lead to a better understanding of MM progression and pathogenesis, and to the development of improved therapies including immunotherapy. A possible mechanism of immunosuppression, which has not been reported yet in MM, is the Accepted article preview online 23 April 2012; advance online publication, 15 May 2012 Letters to the Editor inhibition of T-cell activity by myeloid-derived suppressor cells (MDSCs). MDSCs are a heterogeneous mixture of myeloid cells in different maturation stages that expand in the blood and lymphoid organs of tumor-bearing animals and cancer patients. 5, 6 In mice, MDSCs are defined as CD11b À mononuclear fraction and a Ly6G þ polymorphonuclear fraction. 6 Most of our current knowledge on MDSCs is obtained by studying solid tumors that expand MDSCs in the lymphoid organs, but information on whether cancer cells residing in the BM are able to directly influence MDSC generation in situ is lacking. In this study, we investigated the phenotype, immunosuppressive activity and mechanism of BM MDSC subsets in the syngeneic 5TMM mouse models (5T2MM and 5T33MM). 8 These models are well characterized and closely resemble the human disease. Importantly, the MM cells grow in the BM in fully immunocompetent mice, allowing the study of MDSCs in a relevant in vivo setting. Two subsets of 5T33MM tumor bearers can be identified: '5T33MM high' mice have a high tumor load in the BM (more than 50% cancer cells and typically less than 30% CD11b þ cells in BM), whereas '5T33MM low' have a lower tumor load in the BM (less than 40% cancer cells and more than 50% CD11b þ cells). In a first set of experiments, C57Bl/KaLwRij mice were inoculated with 5T33MM or 5T2MM cells and were killed at the end-stage of the disease, to isolate BM cells from the hind legs and vertebrae, and analyzed for the presence of MDSCs by flow cytometry. Nearly all CD11b high cells co-express Gr-1 in the BM of myeloma-diseased and normal mice ( Figure 1a high population ( Figure 1e ). Interestingly, a recent report has described an increased amount of monocytic CD14 þ HLA-DR À /low cells in the peripheral blood of MM patients at diagnosis compared with healthy donors, suggesting an analogy between patients and MM-diseased mice. 9 Various mechanisms through which MDSC can suppress T-cell proliferation have been reported, including the production of reactive-oxygen species by the NADPH oxidase complex 10 or the concerted action of inducible nitric oxide synthase (iNOS) and arginase, 11 the production of NO by iNOS 6 and the depletion of L-arginine by arginase. 12 The higher immunosuppressive activity of myeloma-derived MDSCs compared with normal MDSCs is accompanied by a higher gene expression of iNOS, arginase-1 and interleukin-10 ( Supplementary Figure 1) . In addition, production of NO by the 5T33MM Ly6G low cells is consistently higher than naive cells (Figure 1f ). NADPH oxidase component gp91phox and COX-2 (generating increased levels of reactive-oxygen species and prostaglandin E 2 , respectively), and inflammatory cytokines such as interleukin-12p40, interleukin-1b and tumor necrosis factor are not induced in 5TMM-stimulated MDSC subsets compared with naive MDSCs (Supplementary Figure 1) . These data illustrate the specific induction of particular genes, with a potential implication in T-cell suppression, in both CD11b high Ly6G low and CD11b high Ly6G high BM cells by MM. To unravel the suppressive mechanism of BM MDSC subsets of MM-diseased mice, specific inhibitors of each pathway were used in ovalbumin-stimulated OT-1/5TMM MDSC cocultures. 5T33MM Ly6G low -mediated suppression was partially, but significantly, reversed by the iNOS inhibitor L-NMMA, whereas the arginase inhibitor norNOHA had no effect, either alone or in combination with L-NMMA (Figure 1g) . Furthermore, the COX-2 inhibitor sc-791 tended to lower suppression, whereas the reactiveoxygen species-scavenging enzymes SOD and catalase even slightly enhance suppression (Figure 1g) . To assess the kinetics of MDSC induction by MM, we investigated the immunosuppressive capacity of 5T2MM Ly6G low and Ly6G high subsets at different time points of disease progression (3, 6, 9, 12 weeks). An increased T-cell suppressive capacity of 5T2MM MDSC subsets could already be observed after 3 weeks (Supplementary Figure 2) -a time point at which the tumor load is very low-and was maintained throughout weeks 6, 9 and 12 (data not shown), indicating that this is an early event in MM disease. Importantly, already at the very early time point, the 5T2MM Ly6G low -mediated suppressive mechanism depends on NO and is enhanced by SOD and catalase (Supplementary Figure 2) . Finally, none of the tested inhibitors/ scavengers is able to reverse the suppression by Ly6G high BM cells from 5T33MM-diseased or 5T2MM-diseased mice (data not shown).
We aimed to further characterize the distinct CD11b high Ly6G low cell types and investigate their relative contribution to T-cell suppression. On the basis of Ly6C expression and SSC profileknown parameters that discriminate between distinct monocytic and granulocytic myeloid cell types 5,6 -three major CD11b high Ly6G low cell types can be discerned in the BM of naive and 5T33MM or 5T2MM-bearing mice (Figure 2a , only shown for 5T33MM): (Figure 2b) . 13 Finally, upon fluorescence-activated cell sorting of the distinct CD11b high Ly6G low subpopulations and T-cell proliferation assays, the data demonstrate that several subpopulations are able to contribute to T-cell suppression, with the monocyte population being the most potent (Figures 2c and d) .
In conclusion, we have demonstrated that immunosuppressive MDSC subsets are present and active in MM, and therefore, MDSCs should be taken into consideration for further studies to improve (immuno)therapy in MM. MDSCs have also been described in other processes. They promote angiogenesis by the expression of matrix high BM subsets compared with isotype controls (red). A similar phenotype is seen in 5T2MM-derived MDSCs (data not shown). (e) Average percentage suppression of T-cell proliferation of naive, 5T2MM or 5T33MM-derived MDSC subsets at a 1:1 MDSC:SPC ratio, taken from multiple independent experiments (n ¼ 7 or more). * and *** indicates Po0.05 and Po0.0004, respectively (Mann-Whitney U-test). Error bars represent s.e.m. T-cell proliferation assays were performed as previously described. 6 (f ) Supernatant from the indicated MDSC:splenocyte co-cultures was taken after 42 h, and the concentration of NO 2 À was measured via Greiss reagent. 6 One representative experiment of two with mean values of triplicates and s.e.m. is shown. (g) 1:1 5T33MM-derived Ly6G
À MDSC:splenocyte cultures were initiated in the presence of the indicated inhibitors/scavengers and percentage suppression was calculated. Inhibitors (0.5 mM L-NMMA, 0.5 mM norNOHA, 100 nM SC-791) and enzymes (1000 U/ml catalase, 200 U/ml superoxide dismutase) were added from the beginning of the culture. Data represent the average % suppression þ s.e.m., taken from at least three independent experiments. * and ** indicates Po0.0051 and Po0.0167, respectively (Mann-Whitney U-test). metalloproteinase-9.
14 Furthermore, MDSCs in 5TMM-bearing mice can differentiate into osteoclasts, thereby contributing to osteolytic bone disease in MM. 15 Hence, targeting MDSCs could not only affect the immune system, but could also modulate angiogenesis and osteolytic bone disease in MM.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission The majority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction therapy. Despite intensive consolidation regimens, less than one-third of adult patients with AML are cured, mainly because of a high incidence of relapse. 1 In a recently published randomized trial, treatment with azacitidine increased the overall survival (OS) relative to supportive care in patients with myelodysplastic syndrome Figure 2 . The presence, phenotype and function of CD11b high Ly6G low MDSC subpopulations in MM. (a) Total BM cells from naive, 5T33MM and 5T2MM tumor-bearers were stained with anti-CD11b/PECy7, anti-Ly6G/FITC, anti-Ly6C/APC and PE-labeled anti-SiglecF, anti-CD115 or anti-CD62L. Staining for CCR2 was performed using a purified anti-CCR2 mAb, followed by PE-labeled anti-ratIgG. 
